<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00588991</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00259</org_study_id>
    <secondary_id>NCI-2009-00259</secondary_id>
    <secondary_id>CDR0000579626</secondary_id>
    <secondary_id>J0783</secondary_id>
    <secondary_id>7968</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>U01CA062491</secondary_id>
    <secondary_id>U01CA069912</secondary_id>
    <secondary_id>U01CA070095</secondary_id>
    <nct_id>NCT00588991</nct_id>
  </id_info>
  <brief_title>Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders</brief_title>
  <official_title>A Phase I Study of ABT-888 in Combination With Topotecan Plus Carboplatin for High-Risk Myeloproliferative Disorders and AML Out of Myeloproliferative Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of veliparib when given
      together with topotecan hydrochloride with or without carboplatin in treating patients with
      relapsed or refractory acute leukemia, high-risk myelodysplasia, or aggressive
      myeloproliferative disorders. Veliparib may stop the growth of cancer cells by blocking some
      of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan
      hydrochloride and carboplatin, work in different ways to stop the growth of cancer cells,
      either by killing the cells or by stopping them from dividing. Giving veliparib together with
      topotecan hydrochloride and carboplatin may kill more cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the feasibility, tolerability, and toxicities of ABT-888 (veliparib) when
      administered alone and in combination with topotecan hydrochloride with or without
      carboplatin in patients with relapsed or refractory acute leukemia, high-risk myelodysplasia,
      or aggressive myeloproliferative disorders.

      II. To determine the maximum tolerated dose of ABT-888 when administered with topotecan
      hydrochloride and carboplatin in these patients.

      III. To determine if ABT-888 when administered with topotecan hydrochloride and carboplatin
      can induce clinical responses in these patients.

      SECONDARY OBJECTIVES:

      I. To determine the pharmacokinetics of ABT-888 when administered alone and in combination
      with topotecan hydrochloride with or without carboplatin in these patients.

      II. To obtain pharmacodynamic data regarding the ability of ABT-888 to inhibit poly
      (ADP-ribose) levels in leukemic blasts.

      III. To obtain descriptive data regarding the mutational status and/or methylation status of
      key genes in selected DNA repair pathways (Fanconi complementation groups A-F, Blooms, and
      ataxia-telangiectasia) in leukemic blasts.

      OUTLINE: This is a multicenter, dose-escalation study of veliparib.

      Patients receive veliparib orally twice daily on days 1-8, 1-14, or 1-21 and topotecan
      hydrochloride with or without carboplatin IV continuously over 120 hours on days 3-7.
      Treatment repeats every 28-63 days for up to 6 courses in the absence of disease progression
      or unacceptable toxicity.

      Patients undergo blood sample collection periodically for pharmacokinetic studies.

      After completion of study therapy, patients are followed for 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 28, 2007</start_date>
  <primary_completion_date type="Actual">February 1, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of veliparib, determined as the highest dose level where 0/3 or 1/6 experience DLT, measured according to NCI-CTCAE 4.0</measure>
    <time_frame>Up to 63 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical response (CR, CRi, PR)</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics and pharmacodynamics of veliparib</measure>
    <time_frame>Day 1 at pre-treatment, .25, .5, 1, 2, 4, 6, and 8 hours after veliparib and day 4 at pre-veliparib, .25, .5, 1, 2, 4, 6, and 8 hours after the first dose of veliparib</time_frame>
    <description>Relevant individual PK parameters will be estimated using non-compartmental PK methods. PK parameters will be compared when administered alone or in combination by a paired student's t-test. Comparison of PK parameters among dose levels will be performed using non-parametric statistical methods for K-independent samples. Associations between exposure parameters (Cmax and AUC) and pharmacodynamic endpoints (cellular PAR levels, mutation and/or altered expression of selected DNA repair genes) will be assessed using the appropriate non-parametric statistical tests.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Adult Acute Megakaryoblastic Leukemia</condition>
  <condition>Adult Acute Monoblastic Leukemia</condition>
  <condition>Adult Acute Monocytic Leukemia</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11</condition>
  <condition>Adult Acute Myeloid Leukemia With Maturation</condition>
  <condition>Adult Acute Myeloid Leukemia With Minimal Differentiation</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1</condition>
  <condition>Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A</condition>
  <condition>Adult Acute Myeloid Leukemia Without Maturation</condition>
  <condition>Adult Acute Myelomonocytic Leukemia</condition>
  <condition>Adult Erythroleukemia</condition>
  <condition>Adult Pure Erythroid Leukemia</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>de Novo Myelodysplastic Syndrome</condition>
  <condition>Essential Thrombocythemia</condition>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia</condition>
  <condition>Polycythemia Vera</condition>
  <condition>Previously Treated Myelodysplastic Syndrome</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Disease</condition>
  <condition>Secondary Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment (veliparib, topotecan hydrochloride, carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive veliparib orally twice daily on days 1-8, 1-14, or 1-21 and topotecan hydrochloride with or without carboplatin IV continuously over 120 hours on days 3-7. Treatment repeats every 28-63 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (veliparib, topotecan hydrochloride, carboplatin)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Treatment (veliparib, topotecan hydrochloride, carboplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (veliparib, topotecan hydrochloride, carboplatin)</arm_group_label>
    <other_name>Hycamptamine</other_name>
    <other_name>Hycamtin</other_name>
    <other_name>SKF S-104864-A</other_name>
    <other_name>Topotecan HCl</other_name>
    <other_name>topotecan hydrochloride (oral)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veliparib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (veliparib, topotecan hydrochloride, carboplatin)</arm_group_label>
    <other_name>ABT-888</other_name>
    <other_name>PARP-1 inhibitor ABT-888</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed diagnosis of 1 of aggressive MPD or AML out of MPD

          -  Aggressive phase high-risk myeloproliferative disorders (i.e., polycythemia vera,
             essential thrombocythemia, or Ph-negative chronic myelogenous leukemia) meeting â‰¥ 1 of
             the following criteria:

               -  Marrow blasts &gt; 5%

               -  Peripheral blood blasts plus progranulocytes &gt; 10%

               -  New onset or increasing myelofibrosis OR;

          -  New onset or &gt; 25% increase in hepatomegaly or splenomegaly

          -  New onset constitutional symptoms (i.e., fever, weight loss, splenic pain, or bone
             pain)

          -  Patients who failed primary induction therapy or relapsed after achieving complete
             remission are eligible

          -  No active CNS leukemia; patients with a history of CNS disease must be stable for &gt; 3
             months after treatment and off steroid treatment prior to study enrollment

          -  Chronic myelomonocytic leukemia meeting either of the following criteria:

               -  5-19% bone marrow blasts (aggressive)

               -  At least 20% marrow blasts (transformation)

          -  ECOG performance status 0-2

          -  No hyperleukocytosis with &gt;= 50,000 blasts/uL

          -  AST, ALT, and alkaline phosphatase =&lt; 5 times upper limit of normal

          -  Bilirubin =&lt; 2.0 mg/dL

          -  Creatinine normal OR creatinine clearance &gt;= 60 mL/min

          -  LVEF &gt;= 45% by MUGA or ECHO

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 30 days after
             completion of study therapy

          -  No active disseminated intravascular coagulation

          -  No active uncontrolled infection

          -  Patients with infection that is under active treatment and controlled with antibiotics
             are eligible

          -  No other life-threatening illness

          -  No mental deficits and/or psychiatric history that would preclude giving informed
             consent or following protocol

          -  No prior or current seizure disorder or a history of seizure

          -  No more than 3 prior cytotoxic regimens

          -  At least 3 weeks since prior cytotoxic chemotherapy

          -  At least 2 weeks since prior radiotherapy

          -  At least 4 weeks since prior autologous or allogeneic stem cell transplantation

          -  No active graft-versus-host disease

          -  At least 1 week since prior biologic therapies, including hematopoietic growth factors

          -  At least 24 hours since prior hydroxyurea, steroids, imatinib mesylate, arsenic
             trioxide, interferon, or other noncytotoxic agents for blast count control

          -  No prior ABT-888

          -  No other concurrent chemotherapy, radiotherapy, or immunotherapy

          -  No concurrent antiretroviral therapy for HIV-positive patients

          -  No other concurrent investigational or commercial agents or therapies for this cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Pratz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University/Sidney Kimmel Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2008</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Leukemia, Monocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Megakaryoblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Veliparib</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

